1. 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. (31st December 2020) Authors: Teichner, Paula; Wu, Sterling; Zhang, Feifan; Dorey, David; D'Amico, Ronald; Griffith, Sandy; Sutton, Kenneth; McCoig, Cynthia C; Upadhyay, Ojesh R; Polli, Joseph; Margolis, David; Van Solingen-Ristea, Rodica; Vandermeulen, Kati; Spreen, William; Patel, Parul Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. (31st December 2020) Authors: Chounta, Vasiliki; Bernal, Enrique; Lombaard, Johan; Katner, Harold P; Walmsley, Sharon; Dorey, David; Spreen, William; Griffith, Sandy; Margolis, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. (15th July 2021) Authors: Cutrell, Amy G.; Schapiro, Jonathan M.; Perno, Carlo F.; Kuritzkes, Daniel R.; Quercia, Romina; Patel, Parul; Polli, Joseph W.; Dorey, David; Wang, Yongwei; Wu, Sterling; Van Eygen, Veerle; Crauwels, Herta; Ford, Susan L.; Baker, Mark; Talarico, Christine L.; Clair, Marty St; Jeffrey, Jerry; Whit... Journal: AIDS Issue: Volume 35:Number 9(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Issue 4 (April 2021) Authors: Orkin, Chloe; Oka, Shinichi; Philibert, Patrick; Brinson, Cynthia; Bassa, Ayesha; Gusev, Denis; Degen, Olaf; García, Juan González; Morell, Enrique Bernal; Tan, Darrell H S; D'Amico, Ronald; Dorey, David; Griffith, Sandy; Thiagarajah, Shanker; St Clair, Marty; Van Solingen-Ristea, Rodica; Crauwel... Journal: Lancet Issue: Volume 8:Issue 4(2021) Page Start: e185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Issue 10101 (23rd September 2017) Authors: Margolis, David A; Gonzalez-Garcia, Juan; Stellbrink, Hans-Jürgen; Eron, Joseph J; Yazdanpanah, Yazdan; Podzamczer, Daniel; Lutz, Thomas; Angel, Jonathan B; Richmond, Gary J; Clotet, Bonaventura; Gutierrez, Felix; Sloan, Louis; Clair, Marty St; Murray, Miranda; Ford, Susan L; Mrus, Joseph; Patel,... Journal: Lancet Issue: Volume 390:Issue 10101(2017) Page Start: 1499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. Issue 4 (3rd September 2019) Authors: Murray, Miranda; Pulido, Federico; Mills, Anthony; Ramgopal, Moti; LeBlanc, Roger; Jaeger, Hans; Canon, Viviam; Dorey, David; Griffith, Sandy; Mrus, Joseph; Spreen, William; Margolis, David Journal: HIV research & clinical practice Issue: Volume 20:Issue 4/5(2019) Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗